Imran Howell, Mahdi Mahdi, Hafiz Taha Mahmood, Laura Bermejo-Sanchez, Catherine Borg, Sanjay Ramakrishnan, J. Mark Melhorn, Gabriel Lavoie, Nayia Petousi, Timothy Hinks, Mona Bafadhel, Ian Pavord
Anti-interleukin (IL)5/5Rα monoclonal antibody (mAb) therapies deplete blood eosinophils and reduce the annualised asthma attack rate by over 50%. The clinical benefits of oral corticosteroids (OCS) to treat breakthrough attacks are uncertain. Fractional exhaled nitric oxide (FENO) has the potential to discriminate between ongoing type-2 airway inflammation or infection in breakthrough attacks on mepolizumab.